莱茵生物(002166) - 2024 Q3 - 季度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of approximately 81.80 million CNY for the first three quarters of 2024, representing a year-on-year increase of 100%-150% compared to a loss of 102.25 million CNY in the same period last year [2]. - The net profit after deducting non-recurring gains and losses is projected to be around 80.77 million CNY, with an expected growth of 2,132.80%-2,698.11% compared to 3.62 million CNY in the previous year [2]. - The basic earnings per share is anticipated to be 0.11 CNY, a significant improvement from a loss of 0.14 CNY per share in the same period last year [2]. - For Q3 2024, the company forecasts a net profit of approximately 16.91 million CNY, marking a year-on-year increase of 259.43%-694.15% compared to a loss of 37.36 million CNY in Q3 2023 [3]. - The net profit after deducting non-recurring gains and losses for Q3 2024 is expected to be around 15.41 million CNY, with a growth of 4,551.80%-10,458.87% compared to a loss of 0.35 million CNY in the same quarter last year [3]. Revenue and Growth Strategy - The company anticipates a revenue growth of approximately 30% year-on-year for the reporting period, driven by a focus on core business development and increased R&D investment [5]. - The company has emphasized enhancing customer service capabilities through customized services and product offerings, contributing to improved market share and profitability [5]. Cautionary Note - The preliminary financial data is subject to final confirmation in the Q3 2024 report, and investors are advised to exercise caution [6].